FDA backs incentives for US manufacturing

The Food and Drug Administration is no longer just regulating drug manufacturing. It is trying to steer where that manufacturing happens. In its fiscal 2027 budget pitch to Congress, the agency backed a set of incentives meant to pull more drug testing and production back into the United States, including a faster path for some early clinical trials and an edge for generic-drug companies that test and make products domestically (statnews.com, fiercepharma.com). That did not appear out of nowhere. The push follows President Donald Trump’s May 5, 2025 executive order on “domestic production of critical medicines,” which told FDA to cut regulatory friction that slows new U.S. plants and makes investment harder to justify. The order argued that new pharmaceutical capacity can take five to ten years to build and singled out the long, uncertain approval process as part of the problem (federalregister.gov). FDA turned that directive into a concrete program last fall, then into pilots this year. The agency’s case is simple. The American drug supply is deeply globalized. At FDA’s own September 30, 2025 public meeting on onshoring, the agency said more than half of pharmaceuticals distributed in the U.S. are manufactured overseas. It also said about 53% of brand drugs and 69% of generic drugs are made outside the country, and only 9% of active pharmaceutical ingredient manufacturers are in the U.S., compared with 22% in China and 44% in India (fda.gov, fda.gov). So FDA has started building incentives around that diagnosis. In October 2025, it launched an ANDA prioritization pilot for generic applications. Companies can qualify for faster review if required bioequivalence testing happens in the United States and the finished product is made here using exclusively domestic sources for active ingredients. That is not subtle policy design. It is an explicit regulatory reward for onshoring (fda.gov). In February 2026, FDA opened a second program called PreCheck. This one is aimed at the factory itself. Instead of waiting until a company files a product application and then discovering problems deep into the process, FDA offers early technical advice, pre-operational reviews, and a facility-specific Drug Master File before the plant is even running. The stated goal is “regulatory predictability,” which in practice means fewer surprises when a company tries to bring a new U.S. site online (fda.gov). Now the budget proposal tries to go further. Reporting on the proposal says FDA wants Congress to create an optional expedited pathway for certain Phase 1 trials, partly because early-stage development has been drifting overseas. The agency also floated new generic-manufacturing incentives in user-fee negotiations, including waiving some facility fees for new domestic operations, though that idea has already met resistance from industry (raps.org, raps.org). The hard part starts after the ribbon cutting. Drug manufacturing is not like moving a warehouse. Shifting a product to a new site, changing an ingredient supplier, or moving analytical testing can trigger validation work, comparability questions, labeling updates, inspection demands, and a burst of post-market noise if anything slips. Complaints can rise. Quality events can cluster. Safety teams can get flooded with cases that are not dramatic enough to make headlines but are serious enough to consume months of work. FDA’s onshoring push is built on the idea that shorter supply chains are safer. The immediate reality is messier: every rushed transfer creates a new place for the system to fail, and the agency is now asking Congress to help it manage that risk while pulling the whole industry inland (statnews.com, fda.gov).